The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19

Maksim V. Baranov, Frans Bianchi, Geert van den Bogaart*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)
17 Downloads (Pure)

Abstract

The PIKfyve inhibitor apilimod is currently undergoing clinical trials for treatment of COVID-19. However, although apilimod might prevent viral invasion by inhibiting host cell proteases, the same proteases are critical for antigen presentation leading to T cell activation and there is good evidence from both in vitro studies and the clinic that apilimod blocks antiviral immune responses. We therefore warn that the immunosuppression observed in many COVID-19 patients might be aggravated by apilimod.

Original languageEnglish
Article number30
Number of pages5
JournalCells
Volume10
Issue number1
DOIs
Publication statusPublished - Jan-2021

Keywords

  • SARS-CoV-2
  • COVID-19
  • apilimod
  • LAM-002A
  • STA-5326
  • PIKfyve

Cite this